NeoGenomics, Inc. (NASDAQ:NEO) Director Alison L. Hannah acquired 20,000 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were purchased at an average price of $9.19 per share, for a total transaction of $183,800.00. Following the purchase, the director now directly owns 38,782 shares of the company’s stock, valued at $356,406.58. The transaction was disclosed in a filing with the SEC, which is available through this link.
Shares of NeoGenomics, Inc. (NASDAQ NEO) opened at 9.16 on Friday. The stock’s 50 day moving average price is $9.20 and its 200-day moving average price is $8.26. The firm’s market capitalization is $727.19 million. NeoGenomics, Inc. has a 12 month low of $6.90 and a 12 month high of $9.93.
NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, July 25th. The medical research company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.03. The company had revenue of $66.09 million for the quarter, compared to the consensus estimate of $62.95 million. NeoGenomics had a positive return on equity of 6.09% and a negative net margin of 2.81%. The company’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.04 earnings per share. On average, equities analysts anticipate that NeoGenomics, Inc. will post $0.18 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “NeoGenomics, Inc. (NASDAQ:NEO) Director Buys $183,800.00 in Stock” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/08/19/neogenomics-inc-nasdaqneo-director-alison-l-hannah-buys-20000-shares-updated-updated.html.
Several analysts have issued reports on NEO shares. BidaskClub upgraded NeoGenomics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. BTIG Research restated a “buy” rating and set a $11.00 price objective on shares of NeoGenomics in a research note on Sunday, May 28th. Zacks Investment Research cut NeoGenomics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 9th. ValuEngine upgraded NeoGenomics from a “sell” rating to a “hold” rating in a research note on Friday, June 23rd. Finally, Cantor Fitzgerald restated a “buy” rating and set a $11.00 price objective on shares of NeoGenomics in a research note on Wednesday, April 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $10.40.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
What are top analysts saying about NeoGenomics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NeoGenomics Inc. and related companies.